Loading…

Determination of metalloproteinases, plasminogen-activators and their inhibitors in the synovial fluids of patients with rheumatoid arthritis during chemical synoviorthesis

The concentrations of matrix metalloproteinase-1 (MMP-1), matrix metalloproteinase-8 (MMP-8), matrix metalloproteinase-9 (MMP-9), lactoferrin and urokinase plasminogen activator (uPA), tissue-type plasminogen activator (tPA) and the inhibitors, tissue inhibitor of metalloproteinase-1 (TIMP-1), plasm...

Full description

Saved in:
Bibliographic Details
Published in:Clinica chimica acta 1996-01, Vol.244 (1), p.17-33
Main Authors: BLÄSER, J, TRIEBEL, S, MAASTJOSTHUSMANN, U, RÖMISCH, J, KRAHL-MATEBLOWSKI, U, FREUDENBERG, W, FRICKE, R, TSCHESCHE, H
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 33
container_issue 1
container_start_page 17
container_title Clinica chimica acta
container_volume 244
creator BLÄSER, J
TRIEBEL, S
MAASTJOSTHUSMANN, U
RÖMISCH, J
KRAHL-MATEBLOWSKI, U
FREUDENBERG, W
FRICKE, R
TSCHESCHE, H
description The concentrations of matrix metalloproteinase-1 (MMP-1), matrix metalloproteinase-8 (MMP-8), matrix metalloproteinase-9 (MMP-9), lactoferrin and urokinase plasminogen activator (uPA), tissue-type plasminogen activator (tPA) and the inhibitors, tissue inhibitor of metalloproteinase-1 (TIMP-1), plasminogen activator inhibitor-1 (PAI-1), plasminogen activator inhibitor (PAI-2), and alpha2-macroglobulin in the synovial fluids of patients with rheumatoid arthritis was determined before and during chemical synoviorthesis with a sodium salt of the fatty acids from cod-liver oil (Varicocid). Synovial fluids were obtained before treatment from 37 patients with rheumatoid arthritis and, in most cases, at 8 and 24 h after injection of the agent. Well-established ELISAs were used to determine the amounts of all proteins. All patients with rheumatoid arthritis revealed very high levels of metalloproteinases (about 1-15 mu g/ml) in their synovial fluids. During the inflammation inducing treatment the granulocyte enzymes increased. In contrast to this, the level of MMP-1 decreased. All granulocyte-derived enzymes were strongly correlated with each other, whereas their dependence on the granulocyte count was only weak. uPA and PAI-2 showed good correlations with the granulocytes-derived enzymes, but were also only weakly correlating with the cell counts. t-PA was not detected by the ELISA used. The proteases, MMP-8, MMP-9 and uPA were increased 8 h after the treatment, whereas the specific inhibitors TIMP-1, PAI-1 and PAI-2 showed significant changes only 24 h after the injection. Matrix metalloproteinases are important factors in the pathogenesis of rheumatoid arthritis. The inflammatory activity in the joint could be better correlated to the granulocyte enzymes than to the granulocyte counts. The levels of uPA and PAI-2 are also parallel to the granulocyte enzyme levels and might underly the same regulatory mechanism.
doi_str_mv 10.1016/0009-8981(95)06172-X
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_78534187</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78534187</sourcerecordid><originalsourceid>FETCH-LOGICAL-p235t-63aecad56c51a2d9fa5057c147f29a63ad2f33f2e7bc8c7a1f367ffb54d101263</originalsourceid><addsrcrecordid>eNo9kM1KJTEQhbNwUEd9A4UsBlGY1k7_93LQcRQENwruLnWTil1Dd9Km0g6-kw85US-SRZHznTohR4hDlZ-pXDXneZ73Wdd36qSvT_NGtUX2uCV2v-Qd8Z35b7pWCW6L7a5X6fS74u0SI4aJHETyTnorJ4wwjn4OPmKSGfmnnEfg5PFP6DLQkV4g-sASnJFxQAqS3EBr-hDJvWuSX51_IRilHRcy_J48pzfQRZb_KA4yDLhMKYeMhBCHQJFYmiWQe5J6wIl0Wv5M8YkjE--LbxZGxoPN3BMPV7_vL66z27s_Nxe_brO5KOuYNSWgBlM3ulZQmN5CndetVlVrix4SNYUtS1tgu9adbkHZsmmtXdeVSWUWTbknjj9zUwnPC3JcTcQaxxEc-oVXbVeXleraZDzaGJf1hGY1B5ogvK429Sb-Y8OB03dsAKeJv2xF31VNo8r_WfyPFw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78534187</pqid></control><display><type>article</type><title>Determination of metalloproteinases, plasminogen-activators and their inhibitors in the synovial fluids of patients with rheumatoid arthritis during chemical synoviorthesis</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>BLÄSER, J ; TRIEBEL, S ; MAASTJOSTHUSMANN, U ; RÖMISCH, J ; KRAHL-MATEBLOWSKI, U ; FREUDENBERG, W ; FRICKE, R ; TSCHESCHE, H</creator><creatorcontrib>BLÄSER, J ; TRIEBEL, S ; MAASTJOSTHUSMANN, U ; RÖMISCH, J ; KRAHL-MATEBLOWSKI, U ; FREUDENBERG, W ; FRICKE, R ; TSCHESCHE, H</creatorcontrib><description>The concentrations of matrix metalloproteinase-1 (MMP-1), matrix metalloproteinase-8 (MMP-8), matrix metalloproteinase-9 (MMP-9), lactoferrin and urokinase plasminogen activator (uPA), tissue-type plasminogen activator (tPA) and the inhibitors, tissue inhibitor of metalloproteinase-1 (TIMP-1), plasminogen activator inhibitor-1 (PAI-1), plasminogen activator inhibitor (PAI-2), and alpha2-macroglobulin in the synovial fluids of patients with rheumatoid arthritis was determined before and during chemical synoviorthesis with a sodium salt of the fatty acids from cod-liver oil (Varicocid). Synovial fluids were obtained before treatment from 37 patients with rheumatoid arthritis and, in most cases, at 8 and 24 h after injection of the agent. Well-established ELISAs were used to determine the amounts of all proteins. All patients with rheumatoid arthritis revealed very high levels of metalloproteinases (about 1-15 mu g/ml) in their synovial fluids. During the inflammation inducing treatment the granulocyte enzymes increased. In contrast to this, the level of MMP-1 decreased. All granulocyte-derived enzymes were strongly correlated with each other, whereas their dependence on the granulocyte count was only weak. uPA and PAI-2 showed good correlations with the granulocytes-derived enzymes, but were also only weakly correlating with the cell counts. t-PA was not detected by the ELISA used. The proteases, MMP-8, MMP-9 and uPA were increased 8 h after the treatment, whereas the specific inhibitors TIMP-1, PAI-1 and PAI-2 showed significant changes only 24 h after the injection. Matrix metalloproteinases are important factors in the pathogenesis of rheumatoid arthritis. The inflammatory activity in the joint could be better correlated to the granulocyte enzymes than to the granulocyte counts. The levels of uPA and PAI-2 are also parallel to the granulocyte enzyme levels and might underly the same regulatory mechanism.</description><identifier>ISSN: 0009-8981</identifier><identifier>DOI: 10.1016/0009-8981(95)06172-X</identifier><identifier>PMID: 8919199</identifier><identifier>CODEN: CCATAR</identifier><language>eng</language><publisher>Shannon: Elsevier</publisher><subject>Adult ; Aged ; alpha-Macroglobulins - analysis ; Arthritis, Rheumatoid - enzymology ; Arthritis, Rheumatoid - therapy ; Biological and medical sciences ; Collagenases - analysis ; Diseases of the osteoarticular system ; Fatty Acids - therapeutic use ; Female ; Glycoproteins - analysis ; Granulocytes - enzymology ; Humans ; Inflammatory joint diseases ; Injections, Intra-Articular ; Knee - pathology ; Knee Joint ; Male ; Matrix Metalloproteinase 1 ; Matrix Metalloproteinase 8 ; Matrix Metalloproteinase 9 ; Medical sciences ; Metalloendopeptidases - analysis ; Metalloendopeptidases - antagonists &amp; inhibitors ; Middle Aged ; Plasminogen Activator Inhibitor 1 - analysis ; Plasminogen Activator Inhibitor 2 - analysis ; Plasminogen Activators - analysis ; Plasminogen Activators - antagonists &amp; inhibitors ; Protease Inhibitors - analysis ; Sclerosing Solutions - therapeutic use ; Synovial Fluid - drug effects ; Synovial Fluid - enzymology ; Tissue Inhibitor of Metalloproteinases</subject><ispartof>Clinica chimica acta, 1996-01, Vol.244 (1), p.17-33</ispartof><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2984661$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8919199$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BLÄSER, J</creatorcontrib><creatorcontrib>TRIEBEL, S</creatorcontrib><creatorcontrib>MAASTJOSTHUSMANN, U</creatorcontrib><creatorcontrib>RÖMISCH, J</creatorcontrib><creatorcontrib>KRAHL-MATEBLOWSKI, U</creatorcontrib><creatorcontrib>FREUDENBERG, W</creatorcontrib><creatorcontrib>FRICKE, R</creatorcontrib><creatorcontrib>TSCHESCHE, H</creatorcontrib><title>Determination of metalloproteinases, plasminogen-activators and their inhibitors in the synovial fluids of patients with rheumatoid arthritis during chemical synoviorthesis</title><title>Clinica chimica acta</title><addtitle>Clin Chim Acta</addtitle><description>The concentrations of matrix metalloproteinase-1 (MMP-1), matrix metalloproteinase-8 (MMP-8), matrix metalloproteinase-9 (MMP-9), lactoferrin and urokinase plasminogen activator (uPA), tissue-type plasminogen activator (tPA) and the inhibitors, tissue inhibitor of metalloproteinase-1 (TIMP-1), plasminogen activator inhibitor-1 (PAI-1), plasminogen activator inhibitor (PAI-2), and alpha2-macroglobulin in the synovial fluids of patients with rheumatoid arthritis was determined before and during chemical synoviorthesis with a sodium salt of the fatty acids from cod-liver oil (Varicocid). Synovial fluids were obtained before treatment from 37 patients with rheumatoid arthritis and, in most cases, at 8 and 24 h after injection of the agent. Well-established ELISAs were used to determine the amounts of all proteins. All patients with rheumatoid arthritis revealed very high levels of metalloproteinases (about 1-15 mu g/ml) in their synovial fluids. During the inflammation inducing treatment the granulocyte enzymes increased. In contrast to this, the level of MMP-1 decreased. All granulocyte-derived enzymes were strongly correlated with each other, whereas their dependence on the granulocyte count was only weak. uPA and PAI-2 showed good correlations with the granulocytes-derived enzymes, but were also only weakly correlating with the cell counts. t-PA was not detected by the ELISA used. The proteases, MMP-8, MMP-9 and uPA were increased 8 h after the treatment, whereas the specific inhibitors TIMP-1, PAI-1 and PAI-2 showed significant changes only 24 h after the injection. Matrix metalloproteinases are important factors in the pathogenesis of rheumatoid arthritis. The inflammatory activity in the joint could be better correlated to the granulocyte enzymes than to the granulocyte counts. The levels of uPA and PAI-2 are also parallel to the granulocyte enzyme levels and might underly the same regulatory mechanism.</description><subject>Adult</subject><subject>Aged</subject><subject>alpha-Macroglobulins - analysis</subject><subject>Arthritis, Rheumatoid - enzymology</subject><subject>Arthritis, Rheumatoid - therapy</subject><subject>Biological and medical sciences</subject><subject>Collagenases - analysis</subject><subject>Diseases of the osteoarticular system</subject><subject>Fatty Acids - therapeutic use</subject><subject>Female</subject><subject>Glycoproteins - analysis</subject><subject>Granulocytes - enzymology</subject><subject>Humans</subject><subject>Inflammatory joint diseases</subject><subject>Injections, Intra-Articular</subject><subject>Knee - pathology</subject><subject>Knee Joint</subject><subject>Male</subject><subject>Matrix Metalloproteinase 1</subject><subject>Matrix Metalloproteinase 8</subject><subject>Matrix Metalloproteinase 9</subject><subject>Medical sciences</subject><subject>Metalloendopeptidases - analysis</subject><subject>Metalloendopeptidases - antagonists &amp; inhibitors</subject><subject>Middle Aged</subject><subject>Plasminogen Activator Inhibitor 1 - analysis</subject><subject>Plasminogen Activator Inhibitor 2 - analysis</subject><subject>Plasminogen Activators - analysis</subject><subject>Plasminogen Activators - antagonists &amp; inhibitors</subject><subject>Protease Inhibitors - analysis</subject><subject>Sclerosing Solutions - therapeutic use</subject><subject>Synovial Fluid - drug effects</subject><subject>Synovial Fluid - enzymology</subject><subject>Tissue Inhibitor of Metalloproteinases</subject><issn>0009-8981</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><recordid>eNo9kM1KJTEQhbNwUEd9A4UsBlGY1k7_93LQcRQENwruLnWTil1Dd9Km0g6-kw85US-SRZHznTohR4hDlZ-pXDXneZ73Wdd36qSvT_NGtUX2uCV2v-Qd8Z35b7pWCW6L7a5X6fS74u0SI4aJHETyTnorJ4wwjn4OPmKSGfmnnEfg5PFP6DLQkV4g-sASnJFxQAqS3EBr-hDJvWuSX51_IRilHRcy_J48pzfQRZb_KA4yDLhMKYeMhBCHQJFYmiWQe5J6wIl0Wv5M8YkjE--LbxZGxoPN3BMPV7_vL66z27s_Nxe_brO5KOuYNSWgBlM3ulZQmN5CndetVlVrix4SNYUtS1tgu9adbkHZsmmtXdeVSWUWTbknjj9zUwnPC3JcTcQaxxEc-oVXbVeXleraZDzaGJf1hGY1B5ogvK429Sb-Y8OB03dsAKeJv2xF31VNo8r_WfyPFw</recordid><startdate>19960115</startdate><enddate>19960115</enddate><creator>BLÄSER, J</creator><creator>TRIEBEL, S</creator><creator>MAASTJOSTHUSMANN, U</creator><creator>RÖMISCH, J</creator><creator>KRAHL-MATEBLOWSKI, U</creator><creator>FREUDENBERG, W</creator><creator>FRICKE, R</creator><creator>TSCHESCHE, H</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19960115</creationdate><title>Determination of metalloproteinases, plasminogen-activators and their inhibitors in the synovial fluids of patients with rheumatoid arthritis during chemical synoviorthesis</title><author>BLÄSER, J ; TRIEBEL, S ; MAASTJOSTHUSMANN, U ; RÖMISCH, J ; KRAHL-MATEBLOWSKI, U ; FREUDENBERG, W ; FRICKE, R ; TSCHESCHE, H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p235t-63aecad56c51a2d9fa5057c147f29a63ad2f33f2e7bc8c7a1f367ffb54d101263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adult</topic><topic>Aged</topic><topic>alpha-Macroglobulins - analysis</topic><topic>Arthritis, Rheumatoid - enzymology</topic><topic>Arthritis, Rheumatoid - therapy</topic><topic>Biological and medical sciences</topic><topic>Collagenases - analysis</topic><topic>Diseases of the osteoarticular system</topic><topic>Fatty Acids - therapeutic use</topic><topic>Female</topic><topic>Glycoproteins - analysis</topic><topic>Granulocytes - enzymology</topic><topic>Humans</topic><topic>Inflammatory joint diseases</topic><topic>Injections, Intra-Articular</topic><topic>Knee - pathology</topic><topic>Knee Joint</topic><topic>Male</topic><topic>Matrix Metalloproteinase 1</topic><topic>Matrix Metalloproteinase 8</topic><topic>Matrix Metalloproteinase 9</topic><topic>Medical sciences</topic><topic>Metalloendopeptidases - analysis</topic><topic>Metalloendopeptidases - antagonists &amp; inhibitors</topic><topic>Middle Aged</topic><topic>Plasminogen Activator Inhibitor 1 - analysis</topic><topic>Plasminogen Activator Inhibitor 2 - analysis</topic><topic>Plasminogen Activators - analysis</topic><topic>Plasminogen Activators - antagonists &amp; inhibitors</topic><topic>Protease Inhibitors - analysis</topic><topic>Sclerosing Solutions - therapeutic use</topic><topic>Synovial Fluid - drug effects</topic><topic>Synovial Fluid - enzymology</topic><topic>Tissue Inhibitor of Metalloproteinases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BLÄSER, J</creatorcontrib><creatorcontrib>TRIEBEL, S</creatorcontrib><creatorcontrib>MAASTJOSTHUSMANN, U</creatorcontrib><creatorcontrib>RÖMISCH, J</creatorcontrib><creatorcontrib>KRAHL-MATEBLOWSKI, U</creatorcontrib><creatorcontrib>FREUDENBERG, W</creatorcontrib><creatorcontrib>FRICKE, R</creatorcontrib><creatorcontrib>TSCHESCHE, H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinica chimica acta</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BLÄSER, J</au><au>TRIEBEL, S</au><au>MAASTJOSTHUSMANN, U</au><au>RÖMISCH, J</au><au>KRAHL-MATEBLOWSKI, U</au><au>FREUDENBERG, W</au><au>FRICKE, R</au><au>TSCHESCHE, H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Determination of metalloproteinases, plasminogen-activators and their inhibitors in the synovial fluids of patients with rheumatoid arthritis during chemical synoviorthesis</atitle><jtitle>Clinica chimica acta</jtitle><addtitle>Clin Chim Acta</addtitle><date>1996-01-15</date><risdate>1996</risdate><volume>244</volume><issue>1</issue><spage>17</spage><epage>33</epage><pages>17-33</pages><issn>0009-8981</issn><coden>CCATAR</coden><abstract>The concentrations of matrix metalloproteinase-1 (MMP-1), matrix metalloproteinase-8 (MMP-8), matrix metalloproteinase-9 (MMP-9), lactoferrin and urokinase plasminogen activator (uPA), tissue-type plasminogen activator (tPA) and the inhibitors, tissue inhibitor of metalloproteinase-1 (TIMP-1), plasminogen activator inhibitor-1 (PAI-1), plasminogen activator inhibitor (PAI-2), and alpha2-macroglobulin in the synovial fluids of patients with rheumatoid arthritis was determined before and during chemical synoviorthesis with a sodium salt of the fatty acids from cod-liver oil (Varicocid). Synovial fluids were obtained before treatment from 37 patients with rheumatoid arthritis and, in most cases, at 8 and 24 h after injection of the agent. Well-established ELISAs were used to determine the amounts of all proteins. All patients with rheumatoid arthritis revealed very high levels of metalloproteinases (about 1-15 mu g/ml) in their synovial fluids. During the inflammation inducing treatment the granulocyte enzymes increased. In contrast to this, the level of MMP-1 decreased. All granulocyte-derived enzymes were strongly correlated with each other, whereas their dependence on the granulocyte count was only weak. uPA and PAI-2 showed good correlations with the granulocytes-derived enzymes, but were also only weakly correlating with the cell counts. t-PA was not detected by the ELISA used. The proteases, MMP-8, MMP-9 and uPA were increased 8 h after the treatment, whereas the specific inhibitors TIMP-1, PAI-1 and PAI-2 showed significant changes only 24 h after the injection. Matrix metalloproteinases are important factors in the pathogenesis of rheumatoid arthritis. The inflammatory activity in the joint could be better correlated to the granulocyte enzymes than to the granulocyte counts. The levels of uPA and PAI-2 are also parallel to the granulocyte enzyme levels and might underly the same regulatory mechanism.</abstract><cop>Shannon</cop><pub>Elsevier</pub><pmid>8919199</pmid><doi>10.1016/0009-8981(95)06172-X</doi><tpages>17</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0009-8981
ispartof Clinica chimica acta, 1996-01, Vol.244 (1), p.17-33
issn 0009-8981
language eng
recordid cdi_proquest_miscellaneous_78534187
source ScienceDirect Freedom Collection 2022-2024
subjects Adult
Aged
alpha-Macroglobulins - analysis
Arthritis, Rheumatoid - enzymology
Arthritis, Rheumatoid - therapy
Biological and medical sciences
Collagenases - analysis
Diseases of the osteoarticular system
Fatty Acids - therapeutic use
Female
Glycoproteins - analysis
Granulocytes - enzymology
Humans
Inflammatory joint diseases
Injections, Intra-Articular
Knee - pathology
Knee Joint
Male
Matrix Metalloproteinase 1
Matrix Metalloproteinase 8
Matrix Metalloproteinase 9
Medical sciences
Metalloendopeptidases - analysis
Metalloendopeptidases - antagonists & inhibitors
Middle Aged
Plasminogen Activator Inhibitor 1 - analysis
Plasminogen Activator Inhibitor 2 - analysis
Plasminogen Activators - analysis
Plasminogen Activators - antagonists & inhibitors
Protease Inhibitors - analysis
Sclerosing Solutions - therapeutic use
Synovial Fluid - drug effects
Synovial Fluid - enzymology
Tissue Inhibitor of Metalloproteinases
title Determination of metalloproteinases, plasminogen-activators and their inhibitors in the synovial fluids of patients with rheumatoid arthritis during chemical synoviorthesis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T13%3A37%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Determination%20of%20metalloproteinases,%20plasminogen-activators%20and%20their%20inhibitors%20in%20the%20synovial%20fluids%20of%20patients%20with%20rheumatoid%20arthritis%20during%20chemical%20synoviorthesis&rft.jtitle=Clinica%20chimica%20acta&rft.au=BL%C3%84SER,%20J&rft.date=1996-01-15&rft.volume=244&rft.issue=1&rft.spage=17&rft.epage=33&rft.pages=17-33&rft.issn=0009-8981&rft.coden=CCATAR&rft_id=info:doi/10.1016/0009-8981(95)06172-X&rft_dat=%3Cproquest_pubme%3E78534187%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p235t-63aecad56c51a2d9fa5057c147f29a63ad2f33f2e7bc8c7a1f367ffb54d101263%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=78534187&rft_id=info:pmid/8919199&rfr_iscdi=true